194 related articles for article (PubMed ID: 36995091)
1. Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy.
Johnson PC; Dhawale T; Newcomb RA; Amonoo HL; Lavoie MW; Vaughn D; Karpinski K; El-Jawahri A
Blood Adv; 2023 Jul; 7(14):3541-3550. PubMed ID: 36995091
[TBL] [Abstract][Full Text] [Related]
2. Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy.
Dhawale TM; Johnson PC; Gaballa MR; Nelson AM; Lavoie MW; Boateng KY; Greydanus C; Frigault MJ; El-Jawahri A
Cancer; 2023 Feb; 129(3):441-449. PubMed ID: 36457279
[TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.
Wang XS; Srour SA; Whisenant M; Subbiah IM; Chen TH; Ponce D; Gonzalez AG; Kamal M; Mendoza T; Cleland CS; Kebriaei P; Neelapu SS; Rezvani K; Ahmed S; Shpall E
Transplant Cell Ther; 2021 Nov; 27(11):930.e1-930.e10. PubMed ID: 34265479
[TBL] [Abstract][Full Text] [Related]
4. Quality of Life and Prognostic Awareness in Caregivers of Patients Receiving Chimeric Antigen Receptor T Cell Therapy.
Barata A; Dhawale T; Newcomb RA; Amonoo HL; Nelson AM; Yang D; Karpinski K; Holmbeck K; Farnam E; Frigault M; Johnson PC; El-Jawahri A
Transplant Cell Ther; 2024 Apr; 30(4):452.e1-452.e11. PubMed ID: 38242441
[TBL] [Abstract][Full Text] [Related]
5. Quality of Life, Physical Functioning, and Psychological Distress of Older Adults Undergoing Hematopoietic Stem Cell Transplantation.
Newcomb R; Johnson PC; Cronin K; Choe JJ; Holmbeck K; Nabily A; Lark P; Rabideau DJ; DeFilipp Z; Chen YB; El-Jawahri A
Transplant Cell Ther; 2023 Jun; 29(6):387.e1-387.e7. PubMed ID: 36958693
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
7. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Kamal M; Joseph J; Greenbaum U; Hicklen R; Kebriaei P; Srour SA; Wang XS
Transplant Cell Ther; 2021 May; 27(5):390.e1-390.e7. PubMed ID: 33965176
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant.
Sidana S; Dueck AC; Thanarajasingam G; Griffin JM; Thompson C; Durani U; Burtis M; Warsame R; Paludo J; Gertz MA; Dispenzieri A; Ansell SM; Rajkumar SV; Yost K; Bennani N; Lin Y; Kumar S
Transplant Cell Ther; 2022 Aug; 28(8):473-482. PubMed ID: 35550440
[TBL] [Abstract][Full Text] [Related]
10. Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma.
Barata A; Hoogland AI; Kommalapati A; Logue J; Welniak T; Hyland KA; Eisel SL; Small BJ; Jayani RV; Booth-Jones M; Oswald LB; Gonzalez BD; Kirtane KS; Jain MD; Mokhtari S; Chavez JC; Lazaryan A; Shah BD; Locke FL; Jim HSL
Transplant Cell Ther; 2022 Jul; 28(7):401.e1-401.e7. PubMed ID: 35580732
[TBL] [Abstract][Full Text] [Related]
11. Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation.
El-Jawahri AR; Vandusen HB; Traeger LN; Fishbein JN; Keenan T; Gallagher ER; Greer JA; Pirl WF; Jackson VA; Spitzer TR; Chen YB; Temel JS
Cancer; 2016 Mar; 122(5):806-12. PubMed ID: 26650840
[TBL] [Abstract][Full Text] [Related]
12. Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy.
Barata A; Hoogland AI; Hyland KA; Otto AK; Kommalapati A; Jayani RV; Irizarry-Arroyo N; Collier A; Rodriguez Y; Welniak TL; Booth-Jones M; Logue J; Small BJ; Jain MD; Reblin M; Locke FL; Jim HSL
Psychooncology; 2021 Aug; 30(8):1294-1301. PubMed ID: 33739548
[TBL] [Abstract][Full Text] [Related]
13. Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy.
Hoogland AI; Barata A; Logue J; Kommalapati A; Hyland KA; Nelson AM; Eisel SL; Small BJ; James BW; Christy SM; Bulls HW; Booth-Jones M; Jayani RV; Jain MD; Mokhtari S; Chavez JC; Lazaryan A; Shah BD; Locke FL; Jim HSL
Transplant Cell Ther; 2022 Jun; 28(6):305.e1-305.e9. PubMed ID: 35378330
[TBL] [Abstract][Full Text] [Related]
14. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
15. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
[TBL] [Abstract][Full Text] [Related]
16. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
17. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
18. Parent Psychological Distress Is Associated with Symptom Burden and Health-Related Quality of Life in Children and Adolescents Undergoing Stem Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy.
Ward J; Smith J; Powers K; Hellsten M; Murray P
Transplant Cell Ther; 2023 Jul; 29(7):462.e1-462.e9. PubMed ID: 37086850
[TBL] [Abstract][Full Text] [Related]
19. Current status of CAR-T cell therapy for pediatric hematologic malignancies.
Hiramatsu H
Int J Clin Oncol; 2023 Jun; 28(6):729-735. PubMed ID: 37154980
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report.
McNerney KO; Richards RM; Aguayo-Hiraldo P; Calkoen FG; Talano JA; Moskop A; Balduzzi A; Krajewski J; Dave H; Vatsayan A; Callahan C; Liu H; Li Y; Davis KL; Maude SL
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36707090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
